News tagged ‘LungCancer’ clear
- After identifying three different types of resistance to a promising investigational lung cancer drug, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors’ constant and varied molecular shape-shifting.
- A study led by Pasi Jänne, MD, PhD, found that an experimental drug targeted to the resistance mutation is highly active in patients with EGFR-positive non-small cell lung cancer (NSCLC) when the disease progressed during treatment with front-line inhibitor drugs.
Tags: LungCancer, Genetics
- Small cell lung cancer – a disease for which no new drugs have been approved for many years – has shown itself vulnerable to an agent that disables part of tumor cells’ basic survival machinery, researchers at Dana-Farber Cancer Institute and the Massachusetts Institute of Technology reported.
Tags: Genomics, LungCancer
- Dana-Farber Cancer Institute and Astellas Pharma Inc. today announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer.
Tags: LungCancer, Partnerships
- The National Cancer Institute (NCI) has launched a new nationwide clinical trial to find out if two molecularly targeted drugs that have improved outcomes in advanced lung cancer can increase survival of patients with early-stage lung cancer that has been surgically removed.
Tags: LungCancer, TargetedTherapy
- Dana-Farber and colleagues from the Cancer Genome Atlas (TCGA) Research Network identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, potentially identifying a greater number of patients with treatable mutations because many potent cancer drugs that target these mutations already exist. Additionally, these findings may expand the number of possible new therapeutic targets for this disease.
Tags: BasicResearch, LungCancer
- Dana-Farber Cancer Institute and its Belfer Institute for Applied Cancer Science are collaborating with Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc., to identify which lung cancer patients would benefit from a new generation of immunotherapies and which combination of such therapies will be the most effective.
Tags: BasicResearch, LungCancer, Immunotherapy
- A new study shows about half of non-small cell lung cancer (NSCLC) patients whose tumors no longer responded to conventional targeted drugs had their tumors shrink after receiving a new, more precisely targeted agent.
Tags: EGFR, LungCancer
- A study 10 years ago discovered a gene mutation that could be treated by a drug that was on the market for something else and changed the way lung cancer patients are treated. It was the start of the era of precision medicine in lung cancer and transformed treatment of the disease.
Tags: EGFR, LungCancer, TargetedTherapy